Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

2(40.0%)

Phase 3

1(20.0%)

5Total

Phase 2(2)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05185089Phase 2Completed

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Role: collaborator

NCT04291755Recruiting

Development and Analysis of a Stool Bank for Cancer Patients

Role: collaborator

NCT02830542Phase 1Completed

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Role: collaborator

NCT02340208Phase 1Completed

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

Role: collaborator

NCT01620762Phase 3Completed

Phase III Cat-PAD Study

Role: collaborator

NCT01949428Completed

House Dust Mite Observational Study

Role: collaborator

NCT01923779Completed

ToleroMune Grass Follow on Study

Role: collaborator

NCT01385800Phase 2Completed

ToleroMune Grass Exposure Unit Study

Role: collaborator

All 8 trials loaded